Sunshine Biopharma Inc (SBFM)

[DragonBear]

I'm all for the plan to generate funding from generic drugs to fund the drug trial in theory, but is it really that easy?

Well, not exactly. First if you look at the 11-May-16 announcement:

pleased to announce that it has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer. Sunshine will market and sell this new pharmaceutical product under its own label.

They admit they must first get Canadian approval to sell a generic. Question: How are they going to manufacture it, and show generic equivalency? Has there been any announcements since 11-May-16 of any Canadian approvals? A manufacturing agreement with a 3rd party?

And what is the competition in the Canadian generic market:

19 generics

One has a Microcrap scam announcing it has a license (from AZN?), with no updates since. They throw out the $255M number for worldwide sales to their SHs, implying millions in Canadian generic sales will just roll in. Neglecting to mention there are already 19 generics in Canada. And if a SBFM managed to get Canadian approval, and line up a manufacturing agreement, could they afford to even compete with major generic companies such as Teva?

IF SBFM ever marketed a Anastrozole generic, it's revenues will be trivial or possibly non-existent. But in the meantime the PR pump is out there. Where they can followup with a bunch of nonsense that they are working on the Canadian filings. Another scam favorite is to claim they have a manufacturing partner, without disclosing the name.

As a side note, the wonderful drug trial which is just Phase I (dose study) is still with a status of "recruiting". With the expected primary completion date of Jul 2017. The preceding company testing the drug managed to get one patent enrolled, who died during treatment. So how many patients have been recruited? Unknown. How many have started treatment, with the status still being "Recruiting"? Unknown. Only SBFM management would presumably know, and they aren't talking. Now what's the harm in SBFM announcing the current patient count? It's also common practice for drug companies to give interim results.

In summary one has a Microcrap still unable to fund beyond Phase I testing, because their generics don't exist. Where they will be "working on it" till infinity. Likewise no news on the drug trial, with the bell set to go off in Jul 2017. Or will they reset the study completion date past Dec 2017, due to lack of enrollment?